| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $62.1M | +166.6% |
| SG&A Expense | $10.3M | +194.2% |
| Operating Income | -$72.3M | -170.2% |
| Pre-tax Income | -$70.0M | -164.3% |
| Income Tax | $0 | — |
| Net Income | -$70.0M | -164.3% |
| EPS (Basic) | -$111.91 | -202.1% |
| EPS (Diluted) | -$111.91 | -202.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $21.8M | -59.0% |
| Current Assets | $152.5M | +174.6% |
| Total Assets | $152.6M | +174.8% |
| Current Liabilities | $9.2M | +94.0% |
| Total Liabilities | $9.2M | +94.1% |
| Stockholders' Equity | -$121.0M | -149.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$71.6M | -202.3% |
| Capital Expenditures | $24K | — |
| Investing Cash Flow | -$118.9M | — |
| Financing Cash Flow | $159.1M | +163.1% |
| Free Cash Flow | -$71.6M | -202.4% |